2Kannel WB, Gordon T, Offutt D, et al. Left Ventricular hypertrophy by eleetroardiogram; prevalence, incidenoe and moratality in the Framingham Study, Ann Intern reed, 1969,71( 1 ) :89-105.
3Segev A,Mekori YA. The cardiac insufficiency bisoprolol study Ⅱ.Lancet, 1999 Apr,353( 9161 ) : 1361.
4Siragy HM,Senbonmatsu T,lehiki T, et al. Increased renal vasodilator prostanoids prevent hypertension in micelaeking the anglotensin subtype - 2 receptor. J Clin Invest, 1999 Jul, 104( 2 ) : 181-8.
5Lipieky RJ. The Rationale behind the United States Food and Drug Administration recommendations. J Hypertens Suppl, 1994 Nov, 12(8) :17-18.
6Neutel J, Weber M, Pool J et al. Valsartan,a new angiotensin Ⅱ antagonist :antihypertensive effects over 24 hours. Clin Ther. 1997,19(3) :447-458.
7Jackson EK,Koehle M, Mi Z. Possible role of adenosine deaminase in vaso - occlusive diseases. JHYPERTENS, 1996,14( ! ) : 19-29.
8Yamada T, Horiuehi M, Dzau VJ. Anglotensin Ⅱ type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA, 1996,93(1): 156-160.
9Siragy HM, Inagami T, Ichiki T. et al. Sustained hypertensitivity to angiotensin Ⅱ and its mechanisem in mice lacking the subtype - 2(AT2) anaiotensin receptor. Prol Natl Acad Sci USA. 1999,96( 11 ) :6506-10.
